Ravoxertinib

Ravoxertinib (GDC-0994) is an orally active ERK kinase inhibitor with an IC50 of 6.1 nM and 3.1 nM for ERK1 and ERK2, respectively.

Product Specifications

CAS Number

[1453848-26-4]

Product Name Alternative

GDC-0994

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

ERK

Type

Reference compound

Related Pathways

MAPK/ERK Pathway; Stem Cell/Wnt

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/GDC-0994.html

Concentration

10mM

Purity

99.84

Solubility

DMSO : ≥ 35 mg/mL

Smiles

O=C1C=C(C2=NC(NC3=CC=NN3C)=NC=C2)C=CN1[C@@H](C4=CC=C(Cl)C(F)=C4)CO

Molecular Formula

C21H18ClFN6O2

Molecular Weight

440.86

Precautions

H302, H315, H319, H335

References & Citations

[1]Blake JF, et al. Discovery of (S) -1- (1- (4-Chloro-3-fluorophenyl) -2-hydroxyethyl) -4- (2- ((1-methyl-1H-pyrazol-5-yl) amino) pyrimidin-4-yl) pyridin-2 (1H) -one (GDC-0994), an Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Inhibitor in Early Clinical Developme|[2]Kirk Robarge, et al. Abstract DDT02-03: Discovery of GDC-0994, a potent and selective ERK1/2 inhibitor in early clinical development. Proceedings: AACR Annual Meeting 2014; April 5-9, 2014.|[3]MICHAEL LAI. Opportunity for Pharmaceutical Intervention in Lung Cancer: Selective Inhibition of JAK1/2 to Eliminate EMT-Derived Mesenchymal Cells.

Shipping Conditions

Room Temperature

Storage Conditions

-20°C, 3 years; 4°C, 2 years (Powder)

Scientific Category

Reference compound1

Clinical Information

Phase 1

Isoform

ERK1; ERK2

Citation 01

ACS Comb Sci. 2019 Dec 9;21 (12) :805-816.|Am J Cancer Res. 2020 Nov 1;10 (11) :3622-3643.|Am J Physiol Heart Circ Physiol. 2018 Mar 1;314 (3) :H580-H592.|Biochem Biophys Res Commun. 2021 May 21:554:63-70.|Biochem Pharmacol. 2025 Jun 6:239:117032.|Cancer Cell. 2023 Jul 10;41 (7) :1345-1362.e9.|Cancer. 2020 Mar 15;126 (6) :1339-1350.|Cancers (Basel) . 2022 Mar 19;14 (6) :1575.|Cancers (Basel) . 2022 May 19;14 (10) :2493.|Cell Death Dis. 2021 Dec 1;12 (12) :1123.|Cell Mol Immunol. 2023 Feb;20 (2) :175-188.|Cell Rep Med. 2025 Feb 6:101970.|Cell Rep. 2023 Sep 1;42 (9) :113048.|Cell Signal. 2023 May:105:110607.|Cell. 2018 Sep 20;175 (1) :186-199.e19.|Clin Transl Med. 2023 Aug;13 (8) :e1381.|Diabetes. 2021 Sep;70 (9) :2131-2146.|Environ Pollut. 2021 Jan 1;268 (Pt B) :115748.|Exp Mol Pathol. 2021 Feb;118:104587.|Gastric Cancer. 2023 May;26 (3) :379-392.|Harvard Medical School LINCS LIBRARY|Indian J Pharm Sci. 2022.|Int Immunopharmacol. 2025 Nov 8;168 (Pt 1) :115798.|Int J Med Sci. 2022 Jan 1;19 (1) :195-204.|iScience. 2024 Sep 12;27 (10) :110873.|J Cell Biochem. 2020 Mar;121 (3) :2343-2353.|J Cell Mol Med. 2020 Sep;24 (17) :10151-10165.|J Exp Clin Cancer Res. 2023 Jul 13;42 (1) :166.|J Pharmacol Exp Ther. 2020 Jul;374 (1) :104-112.|Methods Mol Biol. 2018:1711:351-398.|Mol Oncol. 2020 Nov;14 (11) :2894-2919.|Nat Commun. 2023 Sep 30;14 (1) :6117.|Nat Metab. 2022 Mar;4 (3) :374-388.|Nature. 2025 Jan;637 (8046) :726-735. |Neural Regen Res. 2023 Aug;18 (8) :1743-1749.|Oncogene. 2021 Jul;40 (30) :4884-4893.|Proteomics. 2023 Aug;23 (16) :e2300041.|Redox Biol. 2023 Sep:65:102825.|Reprod Sci. 2020 Feb;27 (2) :704-712.|Sci Transl Med. 2021 Jan 27;13 (578) :eaba7308.|Stem Cell Res Ther. 2025 Jul 1;16 (1) :337.|Toxicol In Vitro. 2020 Jun;65:104777.|Universität Würzburg. Graduate School of Life Sciences. 2021 Jan.|Université de Lausanne. 2024 Feb 7.|Zool Res. 2022 Jul 18;43 (4) :537-551.|ACS Omega. 2023 May 23;8 (22) :19692-19704.|Invest Ophthalmol Vis Sci. 2025 Aug 1;66 (11) :61.|Nucleic Acids Res. 2022 Apr 8;50 (6) :3096-3114.|Pathol Res Pract. 2021 Dec:228:153682.